Free Trial
NASDAQ:IDYA

IDEAYA Biosciences (IDYA) Stock Price, News & Analysis

IDEAYA Biosciences logo
$22.80 -0.17 (-0.74%)
Closing price 04:00 PM Eastern
Extended Trading
$23.07 +0.27 (+1.18%)
As of 04:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About IDEAYA Biosciences Stock (NASDAQ:IDYA)

Key Stats

Today's Range
$21.97
$23.06
50-Day Range
$17.10
$22.97
52-Week Range
$13.45
$44.42
Volume
1.22 million shs
Average Volume
1.01 million shs
Market Capitalization
$2.00 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$47.55
Consensus Rating
Moderate Buy

Company Overview

IDEAYA Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
73rd Percentile Overall Score

IDYA MarketRank™: 

IDEAYA Biosciences scored higher than 73% of companies evaluated by MarketBeat, and ranked 309th out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    IDEAYA Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.85, and is based on 9 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    IDEAYA Biosciences has only been the subject of 4 research reports in the past 90 days.

  • Read more about IDEAYA Biosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for IDEAYA Biosciences are expected to decrease in the coming year, from ($3.07) to ($3.20) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of IDEAYA Biosciences is -6.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of IDEAYA Biosciences is -6.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    IDEAYA Biosciences has a P/B Ratio of 1.86. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about IDEAYA Biosciences' valuation and earnings.
  • Percentage of Shares Shorted

    14.39% of the float of IDEAYA Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    IDEAYA Biosciences has a short interest ratio ("days to cover") of 8.
  • Change versus previous month

    Short interest in IDEAYA Biosciences has recently increased by 8.00%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    IDEAYA Biosciences does not currently pay a dividend.

  • Dividend Growth

    IDEAYA Biosciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    14.39% of the float of IDEAYA Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    IDEAYA Biosciences has a short interest ratio ("days to cover") of 8.
  • Change versus previous month

    Short interest in IDEAYA Biosciences has recently increased by 8.00%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    IDEAYA Biosciences has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for IDEAYA Biosciences this week, compared to 6 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, IDEAYA Biosciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.50% of the stock of IDEAYA Biosciences is held by insiders.

  • Percentage Held by Institutions

    98.29% of the stock of IDEAYA Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about IDEAYA Biosciences' insider trading history.
Receive IDYA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IDEAYA Biosciences and its competitors with MarketBeat's FREE daily newsletter.

IDYA Stock News Headlines

IDYA - IDEAYA Biosciences Inc Financials - Morningstar
How a Kansas farm boy gained 1,285% in two days
A former farm kid placed a simple trade… and cashed out a 1,285% gain two days later. It wasn’t crypto or a meme stock. It was a pattern called “Crossfire” — a 3-step setup you can execute in a normal brokerage app. Master trader Jeff Clark is now revealing how it works in a free 30-minute video, available for a limited time.
See More Headlines

IDYA Stock Analysis - Frequently Asked Questions

IDEAYA Biosciences' stock was trading at $25.70 at the start of the year. Since then, IDYA stock has decreased by 11.3% and is now trading at $22.80.

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) released its quarterly earnings data on Tuesday, May, 6th. The company reported ($0.82) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by $0.07.

IDEAYA Biosciences (IDYA) raised $70 million in an initial public offering on Thursday, May 23rd 2019. The company issued 5,000,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan, Citigroup and Jefferies acted as the underwriters for the IPO.

Top institutional shareholders of IDEAYA Biosciences include Parallel Advisors LLC. Insiders that own company stock include Yujiro S Hata, Briseno Andres Ruiz, Paul A Stone, Michael Anthony White and Jason Throne.
View institutional ownership trends
.

Shares of IDYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that IDEAYA Biosciences investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET), e.l.f. Beauty (ELF) and ServiceNow (NOW).

Company Calendar

Last Earnings
5/06/2025
Today
7/10/2025
Next Earnings (Estimated)
8/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:IDYA
CIK
1676725
Fax
N/A
Employees
80
Year Founded
N/A

Price Target and Rating

High Price Target
$68.00
Low Price Target
$25.00
Potential Upside/Downside
+109.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.85
Research Coverage
13 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.59)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$274.48 million
Net Margins
N/A
Pretax Margin
-4,386.90%
Return on Equity
-29.28%
Return on Assets
-27.68%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
13.92
Quick Ratio
13.92

Sales & Book Value

Annual Sales
$7 million
Price / Sales
283.68
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$12.25 per share
Price / Book
1.85

Miscellaneous

Outstanding Shares
87,582,000
Free Float
85,392,000
Market Cap
$1.99 billion
Optionable
Optionable
Beta
0.03
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:IDYA) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners